ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2013

Abstract Number: 2620

Development Of De Novo Major Involvement During The Follow-Up In Behçet’s Disease

Claudia Ferrari1, Rosaria Talarico2, Chiara Stagnaro3, Anna d'Ascanio4, Chiara Tani3, Chiara Baldini3, Marta Mosca1 and Stefano Bombardieri3, 1Rheumatology Unit, University of Pisa, Pisa, Italy, 2Rheumatology Unit, Pisa, Italy, 3University of Pisa, Rheumatology Unit, Pisa, Italy, 4Malattie muscolo-scheletriche e cutanee, Rheumatology Unit, Pisa, Italy

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2013

Keywords: Behcet's syndrome

Session Information

Title: Vasculitis III

Session Type: Abstract Submissions (ACR)

Background/Purpose: Behçet’s disease (BD) is globally characterized by a variable spectrum of disease profile: while prevalent muco-cutaneous lesions and arthritis represent the only clinical features in patients with a benign disease subset, there are other patients who develop potentially sight or life-threatening manifestations, due to ocular, neurological or major vascular involvement. The primary aim of the study was to evaluate the incidence of the novo major involvement during the follow-up in a cohort of  patients with BD; the secondary aim was to analyze the epidemiological profile and the long-term outcome of those patients who developed de novo major involvement.

Methods:  One hundred and twenty patients were evaluated. The male/female ratio was 1.6:1, with a mean disease duration of 11±5 years. Their mean age was 42±9 years (min:18, max:77), while the mean age at disease onset was 25±4 years (min:10, max:58). The mean ± SD duration of follow-up at our centre was 8±2 (min:2, max:12) years. We have defined the development of de novo major involvement during the follow-up as the occurrence of severe ocular (anterior uveitis, posterior uveitis, retinal vasculitis), vascular (deep vein thrombosis, superficial vein thrombosis, arterial thrombosis, arterial aneurysm) or CNS (ischaemic pons-mesencephalon lesions and meningoencephalitis) involvement after a latency period from the diagnosis of at least 3 years

Results: At the time of diagnosis, the 52% of the cohort (n=62) presented a prevalent muco-cutaneous involvement. Among this sub group of patients, we observed that after at least 3 years from the diagnosis, 21 patients (34%)  was characterized by the occurrence of de novo major involvement (i.e. ocular: 3; CNS: 9; vascular: 9). The demographic profile of this subgroup (male: 19, female: 2) was characterized by a mean age of 33±4 years (min 24-max 40) and a young age at disease onset. The long term outcome after a mean follow-up of 8 years has shown that the majority of these subjects presented during the disease course also relapsing attacks. Moreover, they were characterized by a bigger number of DMARDs (both traditional and anti TNF-alpha)  compared to the other part of the cohort

Conclusion: As awaited, younger age and male sex represent predictive factors of poor long-term clinical outcome. We have found that ocular disease seems the organ involvement that more frequently has an onset before the first years of disease. Globally, he development of the novo major involvement during the course of BD represents an entity that may confirm that a tight control is strongly recommended during the course of BD


Disclosure:

C. Ferrari,
None;

R. Talarico,
None;

C. Stagnaro,
None;

A. d’Ascanio,
None;

C. Tani,
None;

C. Baldini,
None;

M. Mosca,
None;

S. Bombardieri,
None.

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-de-novo-major-involvement-during-the-follow-up-in-behcets-disease/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology